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A  signiﬁcant  percentage  of  cancer  patients  develop  secondary  lymphedema  after surgery  or  radiother-
apy. The  preferred  treatment  of  secondary  lymphedema  is  complex  physical  therapy.  Pharmacotherapy,
for  example  with  diuretics,  has received  little  attention,  because  they  were  not effective  and  only offered
short-term  solutions.  Sodium  selenite  showed  promise  as a cost-effective,  nontoxic  anti-inﬂammatory
agent.  Treatment  with sodium  selenite  lowers  reactive  oxygen  species  (ROS)  production,  causes  a  sponta-odium selenite
elenium
ymphedema
xidative stress
nﬂammation
ymphedema therapy
neous reduction  in  lymphedema  volume,  increases  the  efﬁcacy  of physical  therapy  for  lymphedema,  and
reduces  the incidence  of  erysipelas  infections  in  patients  with  chronic  lymphedema.  Besides  biological
effects  in  reducing  excessive  production  of  ROS,  sodium  selenite  also  displays  various  pharmacological
effects.  So  far  the exact  mechanisms  of  these  pharmacological  effects  are  mostly  unknown,  but  probably
include  inhibition  of adhesion  protein  expression.
©  2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Secondary lymphedema is a common side effect of cancer treat-
ent. The incidence rate varies greatly because of the absence
f uniform measurement, deﬁnition and reporting [1]. Most data
s available for breast cancer survivors. The incidence rates range
related limbs. The subsequent tissue swelling can cause pain, dis-
comfort, heaviness, distortion, and reduced mobility and function
[2]. Both physical and mental quality of life is affected [3].
Currently, there is no curative therapy available. It can only be
managed. The goal is to decrease limb size and maintain it, pre-
vent complications, improve limb function, and overall well beingetween 13% to 65% [1]. Secondary lymphedema occur after lymph
ode resection. Lymph drainage routes can be damaged, which
auses accumulation of lymph ﬂuid in the interstitial tissue of
∗ Corresponding author.
E-mail address: chpﬁster@t-online.de (C. Pﬁster).
ttp://dx.doi.org/10.1016/j.jtemb.2016.05.005
946-672X/© 2016 The Authors. Published by Elsevier GmbH. This is an open access artic
.0/).[4]. The most important treatment is complex physical therapy,
which includes complete decongestive therapy. It also consists of
manual lymph drainage, exercise, nonelastic wrapping, use of com-
pression garments, and skin care [1]. A second therapy option is
low-level laser therapy, which can effectively reduce limb volume,
extracellular ﬂuid, and tissue hardness in one third of breast cancer
patients [5,6]. Pharmacotherapy has received little attention, prob-
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
Selenium status in lymphedema and/or lipedema patients in Germany. Mean
value ± standard deviation.
Subgroups patient number whole blood selenium
concentration [g/l]
overall 234 102.4 ± 19.8
lipedema 101 99.4 ± 18.0
lymphedema 160 103.8 ± 21.6
lymphostatic elephantiasis 14 87.5 ± 18.3
primary lymphedema 32 114.2 ± 27.2
secondary lymphedema 60 102.7 ± 19.8
lymphedema stage I 9 109.1 ± 17.9
lymphedema stage II 80 106.5 ± 23.9
lymphedema stage III 27 91.5 ± 14.4
cancer-related lymphedema 31 106.5 ± 19.4
mamma  carcinoma + lymphedema 11 107.6 ± 15.4
diabetes + lymphedema 9 95.2 ± 15.5
hypothyroidism + lymphedema 20 103.6 ± 14.5
obese + lymphedema 92 100.0 ± 19.612 C. Pﬁster et al. / Journal of Trace Element
bly because many drugs were not effective and only very few offer
ong-term solutions [1].
Paskett et al. mentioned only one drug, sodium selenite, in a
eview regarding cancer-related lymphedema [1]. The authors con-
luded, that sodium selenite shows promise as a cost-effective,
ontoxic anti-inﬂammatory agent [1]. The Cochrane analysis on
elenium in cancer patients from 2006 included two  trials from
asseroller et al. and Zimmermann et al. [7,8]. The authors
oncluded, that sodium selenite might reduce the incidence of
ecurrent erysipelas infections after breast cancer treatment, but
he results should be interpreted with caution and should not be
eneralized to other populations [9].
This review summarizes the current literature regarding sodium
elenite in lymphedema treatment with emphasis on probable
ode of action of sodium selenite.
.1. Lymphedema
The Iowa women’s health study provided new data regarding
ymphedema in breast cancer survivors [3]. The study included
,287 women with unilateral breast cancer. 8.1% were diagnosed
ith lymphedema. Further 37.2% women reported arm symptoms
ithout diagnosed lymphedema. After multivariate adjustment,
oth women with diagnosed lymphedema and women  with arm
ymptoms had lower physical and mental health related quality
f life (HRQOL) (Medical Outcomes Study Short Form-36). Only
alf of the women with diagnosed lymphedema received treatment
51.5%). Furthermore, only 39.8% of the women with arm symptoms
ver heard of lymphedema. This lack of knowledge about lym-
hedema may  prevent woman with arm symptoms from seeking
valuation or treatment as only 10.3% talked to their practitioner
bout the different appearance of one arm and only 1.7% received
reatment [3].
A 5-year, population-based prospective study (n = 6,319) evalu-
ted the incidence, degree, time course, treatment, and symptoms
f lymphedema in breast cancer patients after tumor resection [10].
he ﬁve-year cumulative incidence of lymphedema was 42 (42%)
er 100 women. Incidence was higher for woman <50 years (50%)
ompared to woman >80 years (26%). In the ﬁrst three years 23%
eported no more than mild lymphedema, 12% reported moderate
r severe lymphedema, and 2% reported a chronically moderate
r severe form. 47.3% of the women with lymphedema received
t least one type of treatment. Women  with moderate or severe
ymphedema were more likely to be treated (68% vs. 37%). Mostly
xercise, sleeve, elevation, or massage was used for therapy. The
tudy also showed, that symptoms before the ﬁrst occurrence of
ymphedema, for example jewelry too tight or clothing too tight,
ere associated with higher probability of later lymphedema (Haz-
rd Ratio (HR) 7.37; 95% CI, 4.26–12.76, respectively HR 5.47; 95%
I 1.98–15.10). Till now, there was no investigation, if a prompt
reatment of those early symptoms can prevent lymphedema or
rogression from mild to moderate or severe form.
The incidence rate is much higher after the resection of head and
eck tumors. Three-quarter of the patients have some form of late-
ffect lymphedema [11]. Most patients displayed a combination of
xternal and internal lymphedema (50.8%). External lymphedema
tage I affected 18.5% of the patients, and 27.2% displayed stage II
ymphedema. Internal lymphedema were graded as moderate in
5.5% and as severe in 20% of the cases.
.2. Selenium status of patients with lymphedemaSelenium status of patients with lymphedema and/or lipedema
as determined in a new study. Selenium concentration in
hole blood was measured in 234 patients, which were treated
or lymphedema in a specialist clinic in Germany (Lympho-Optmorbidly obese + lymphedema 24 94.7 ± 15.5
Clinic Pommelsbrunn-Hohenstadt, Germany). Selenium measure-
ment was performed using microwave digestion and ﬂameless
atomic absorption spectrometry in a certiﬁed laboratory (biosyn
Arzneimittel GmbH, Fellbach, Germany).
The mean selenium concentration was  102.4 ± 19.8 g/l. The
German authorities deﬁned a selenium deﬁcit as values below
100 g/l selenium in whole blood [12]. Using this parameter 44%
of the patients exhibited a selenium deﬁcit. Signiﬁcantly more
patients with lymphedema stage III displayed reduced selenium
levels (78% vs. 44%; p = 0.001).
The comparison of selenium values in lymphedema and
lipedema showed no signiﬁcant difference (103.8 ± 21.6 g/l vs.
99.4 ± 18.0 g/l) (Table 1). But patients with lymphostatic elephan-
tiasis (stage three lymphedema and/or lipedema) displayed the
lowest selenium values (87.5 ± 18.3 g/l; p = 0.014). Selenium con-
centration was higher in primary lymphedema (114.2 ± 27.2 g/l
vs. 103.8 ± 21.6 g/l; p = 0.0312). There was also a strong trend
regarding a signiﬁcant difference between primary and secondary
lymphedema (114.2 ± 27.2 g/l vs. 102.7 ± 19.4 g/l; p = 0.056)
(Fig. 1).
Furthermore, selenium status declined with increasing lym-
phedema stage. Selenium concentration was signiﬁcantly reduced
in lymphedema stage III compared to stage I and II (91.5 ± 14.4 g/l;
p = 0.0109 respectively p = 0.0002) (Fig. 2).
Patients with cancer related lymphedema showed no sig-
niﬁcantly reduced selenium status compared to other patients
with secondary lymphedema (106.5 ± 19.4 g/l vs. 102.7 ± 19.8;
p = 0.4717). 39% of the lymphedema and/or lipedema patients were
obese. While selenium level was  not signiﬁcantly different in obese
patients, morbidly obese patients displayed signiﬁcantly reduced
whole blood selenium concentration compared to all patients
(103.8 ± 21.6 g/l vs. 94.7 ± 15.5; p = 0.0398).
Surprisingly, selenium status was higher in patients with
primary lymphedema compared to patients with secondary lym-
phedema. While the underlying causes are different for primary
and secondary lymphedema, the consequences, which result in the
development of lymphedema, are similar. At the moment, there is
no explanation for higher selenium status in primary lymphedema,
especially as patients with lymphostatic elephantiasis, regardless
of lymphedema type, displayed the lowest mean selenium values.
In women BMI  ≥ 30 kg/m2 is signiﬁcantly associated with
reduced selenium status (p = 0.01) [13]. Morbidly obese patients
(BMI ≥ 40 kg/m2) display signiﬁcantly reduced serum selenium
concentration (86.08 g/l vs. 101.14 g/l; p < 0.0001) [14]. Signif-
icantly reduced selenium status in morbidly obese patients is
probably due to obesity related oxidative stress [15]. Also, obe-
C. Pﬁster et al. / Journal of Trace Elements in Medicine and Biology 37 (2016) 111–116 113
Fig. 1. Selenium concentration in whole blood was  signiﬁcantly increased in pri-
mary lymphedema. The comparison between primary and secondary lymphedema
displayed a strong trend for reduced selenium status in secondary lymphedema.
Statistical signiﬁcance was  calculated using the non-parametric Mann-Whitney U
test;  p-values < 0.05 were considered statistically signiﬁcant. Data were analyzed
and ﬁgures were created using GraphPadPrism 6 (GraphPad Software, Inc., La Jolla,
CA,  USA).
Fig. 2. Selenium concentration in whole blood decreased with increasing lym-
phedema stage. Statistical signiﬁcance was  calculated using the non-parametric
Mann-Whitney U test; p-values < 0.05 were considered statistically signiﬁcant. Data
were analyzed and ﬁgures were created using GraphPadPrism 6 (GraphPad Soft-
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sodium selenite pre-, intra- and post operation. From day 1–21
sodium selenite dosage was  1,000 g selenium per day intra-are, Inc., La Jolla, CA, USA).
ity is associated with a state of chronic inﬂammation, which also
ontributes toward a pro-oxidant environment in obesity [16].
The study showed that patients with severe lymphedema were
igniﬁcantly more often affected by reduced selenium levels. Those
esults strongly indicate an increased selenium requirement in
hese patients. The cause for increased selenium requirement
ould be enhanced oxidative stress and an elevated inﬂamma-
ory activity. Siems et al. determined, that in the tissue of chronic
ymphedema the formation of reactive oxygen species (ROS) was
nhanced and lipid peroxidation processes were accelerated [17].Fig. 3. Sodium selenite reduced lymphedema volume and improved efﬁ-
ciency of complex physical therapy [19]. GPx–1 = glutathione peroxidase 1;
GPx–4 = glutathione peroxidase-4.
1.3. Sodium selenite treatment for secondary lymphedema
As Micke et al. stated, selenium has a proven antiedematous
effect, which is neither widely published nor accepted [18]. Sev-
eral trials with oral sodium selenite treatment showed, that sodium
selenite lowers ROS production, causes a spontaneous reduction in
lymphedema volume, increases the efﬁcacy of physical therapy for
lymphedema, and reduces the incidence of erysipelas infections in
patients with chronic lymphedema [18]. The results of these trials
are summarized below (Table 2).
Kasseroller et al. evaluated the effect of oral sodium selen-
ite in combination with combined physical decongestive therapy
in 179 lymphedema patients [19]. The intervention period was
three weeks. In the ﬁrst week daily sodium selenite treatment was
1,000 g selenium. In the second and third week 300 g selenium
per day were supplemented. Follow-up period was  three months.
During this period patients received 100 g selenium per day.
The lymphedema volume was signiﬁcantly more reduced in the
intervention group compared to combined physical decongestive
therapy alone (- 52.0 ± 18.0% vs. 43.0% ± 16.0%; p < 0.01) [19]. Also
the skin fold index and mobility were signiﬁcantly more improved
with sodium selenite treatment (p < 0.05 respectively p < 0.001)
[19]. In the sodium selenite supplemented group the erysipelas
incidence was  0% compared with 50% in the placebo group [19].
Micke et al. determined the effect of oral sodium selen-
ite in radiation-associated secondary lymphedema [20]. In this
exploratory study 48 patients were treated with up to 500 g
selenium per day for 4–6 weeks. Twelve patients displayed lym-
phedema of the arm and 36 patients lymphedema of the head
and neck region. More than three-quarter of the patients showed
an improvement of one stage or more according to the Földi and
Miller score [20]. 65% of patients with interstitial grade III or IV
endolaryngeal lymphedema displayed a substantial reduction in
endolaryngeal swelling [20]. Therefore, no tracheotomy was  nec-
essary in these patients.
These results were conﬁrmed in a double-blind, randomized,
prospective study [8]. Zimmermann et al. treated 20 patients with
oral surgery intravenously with 1,000 g selenium in form ofvenously or orally. The lymphedema volume reduced signiﬁcantly
after one week in the sodium selenite supplemented group (-
114 C. Pﬁster et al. / Journal of Trace Elements in Medicine and Biology 37 (2016) 111–116
Table  2
Lymphedema trials with sodium selenite.
trial intervention results
Kasseroller et al. [19]
placebo-controlled, double blind
N = 179
intervention group n = 90
placebo group n = 89
Breast cancer patients
baseline whole blood concentration
69 ± 8 g/l
selenium as sodium selenite
Week 1:
1,000 g per day
Week 2 + 3:
300 g per day
Follow-up period (3 month):
100 g per day
Increased whole blood selenium concentration after 3
weeks (112 ± 24 g/l; p < 0.001)
Reduced lymphedema volume compared to placebo group
(p  < 0.01)
Improved skin fold index and mobility (p < 0.05 and
p  < 0.001)
Reduced erysipelas incidence (0% vs. 50%)
Micke  et al. [20]
N = 48
Breast cancer (n = 12)
head and neck cancer (n = 36)
selenium as sodium selenite
4–6 weeks:
500 g per day
Lymphedema improvement of one stage or more (Földi
and Miller score)
Reduction in endolaryngeal swelling
Zimmermann et al. [8]
Prospective, randomized, placebo-controlled,
double-blind
N = 20
selenium as sodium selenite
1,000 g pre, intra, and post operation
1,000 g for 21 days
Increased whole blood selenium concentration after
operation, week 1 and week 2 (p = 0.001, p = 0.002,
p = 0.000)
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aintervention group n = 10
placebo group n = 10
squamous cell carcinoma of the head and neck
%; p = 0.009). The severity of the lymphedema was negatively
orrelated with blood selenium concentration and glutathione per-
xidase activity. Also ROS concentration was positively correlated
ith the extent of lymphedema.
.4. Biological effect of sodium selenite treatment
In lymphedema tissue oxygen supply is restricted, giving rise to
he excessive production of ROS [21]. The excessive amount of ROS
nduces an inﬂammatory reaction and affected lymph vessels are
nvaded by phagocytes and other activated leucocytes. The ensu-
ng respiratory burst triggers a cascade of peroxidative reactions,
hich results in the formation of 4-hydroxynonenal (4-HNE) and
alondialdehyde (MDA) as measured in erythrocytes and blood
erum [19]. Those metabolites display proinﬂammatory [22], vaso-
onstrictive [23], cytotoxic [24] and potential carcinogenic [25]
roperties. To detoxify those metabolites high amounts of glu-
athione (GSH) are used and oxidized (GSSG). Siems et al. showed
hat GSH concentration in blood was decreased in chronic lym-
hedema patients and GSSG was elevated, resulting in a threefold
igher glutathione ratio, an indicator for oxidative stress [17].
The concentration of lipid peroxidation products MDA  and 4-
NE increased threefold in the serum of lymphedema patients,
espectively twofold [17]. Lymphedema patients treated with oral
odium selenite displayed a rapid increase in GSH and a slower
ecrease in GSSG as well as 4-HNE measured in erythrocytes,
espectively blood serum [26]. Selenium as part of selenopro-
eins thioredoxin reductase and glutathione peroxidase is essential
or redox reactions. Therefore sodium selenite supplementation
robably increased activity of these selenoproteins elevating GSH
oncentration and decreasing GSSG level. The increased GSH con-
entration could also reverse the effect of GSH depletion, which
mpedes the function of glutathione peroxidase.
One of the most important intracellular antioxidant enzymes
s the selenoprotein glutathione peroxidase. The crucial fac-
or for biosynthesis of glutathione peroxidase is availability
f selenium. High dose sodium selenite increased glutathione
eroxidase activity noticeably at day three in sepsis patients
27]. Selenium deﬁciency signiﬁcantly reduces liver glutathione
eroxidase-1 activity, the most common selenoprotein [28].
nother selenoprotein, thioredoxin reductase, is also capable to
egrade hydroperoxide [29]. Selenoproteins with extracellular
ntioxidant functions are glutathione peroxidase 3 and selenopro-Reduced lymphedema volume compared to placebo group
(p  = 0.009)
tein P, whereby selenoprotein P is also the transport protein for
selenium [29].
A functional gene expression analysis of a mouse model of acute,
acquired lymphedema showed that whole panels of genes involved
in the immune response, stress response, and complement acti-
vation were induced in lymphedema tissue [30]. These included
several selenoproteins. The fold-change was  highest for selenopro-
tein P (2.8:1), selenoprotein W (2.2:1), and glutathione peroxidase
1 (1.9:1). Also selenoprotein K was  upregulated. These results con-
ﬁrmed the important role of selenoproteins in lymphedema. Most
of the upregulated selenoproteins are so-called stress-responsive
selenoproteins. They are highly dependent on an adequate sele-
nium supply. Even marginal selenium deﬁciency prevents maximal
activity for example for glutathione peroxide 1, which requires
selenium concentration of 95 g/l in blood plasma [31]. In the
trial by Hurst et al. optimal concentration of selenoprotein P was
reached at 124 g/l selenium in plasma [32].
Besides their antioxidant capacity selenoproteins also play a
major role in the immune system. Adequate selenium status is
important for initiating immunity. But selenoproteins are also
involved in regulating excessive immune response and chronic
inﬂammation [33]. Selenium deﬁciency has been recognized to
negatively impact immune cells during activation, differentiation,
and proliferation [33]. Besides those effects based on increased
oxidative stress, selenoproteins are linked to protein folding and
calcium ﬂux [33]. Huang et al. provided an in depth review about
the role of selenoproteins in inﬂammation and immunity [33].
In summary, not only an adequate selenium supply is neces-
sary to decrease excessive ROS production in lymphedema, but
the selenium requirement is probably higher compared to healthy
people.
1.5. Pharmacological effect of sodium selenite treatment
The ﬁrst evidence, that sodium selenite has beneﬁcial effects
in chronic lymphedema were noted in 1991 [19]. A patient with
acutely inﬂamed lymphedema of the arm was treated with 800 g
selenium in form of sodium selenite orally. Ten to ﬁfteen min-
utes after the supplementation the inﬂammation and edema were
visibly reduced [19]. This fast reaction can not be explained
with sole biological effects of sodium selenite. Therefore, sodium
selenite probably also displays direct pharmacological effects in
lymphedema tissue.
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Deranged immune trafﬁc plays a role in the pathogenesis of
ymphedema [30]. In normal immune trafﬁc, mononuclear phago-
ytes and lymphocytes enter the afferent lymph vessels and the
ymph nodes to elicit primary immune response before reentering
he vasculature [34]. In chronic lymphedema, the impairment of
ymphocytes trafﬁcking from skin to regional lymph nodes leads to
nefﬁcient clearance of foreign antigens, which provides the sub-
trate for chronic inﬂammatory changes [30].
In 2000, Kasseroller et al. postulated a hypothesis how sodium
elenite exerts pharmacological effects in lymphedema [19]. They
roposed that sodium selenite inhibits the expression of adhesion
roteins. The excessive amount of ROS induces an inﬂammatory
eaction and affected lymph vessels are invaded by phagocytes and
ther activated leucocytes. Adhesion molecules on the surface of
mmune cells attach to the walls of lymph capillaries [19]. As a
esult venous lymphatic insufﬁciency increases further. Inhibition
f adhesion proteins reduces the ability of immune cells to attach
o lymph capillaries. Venous lymphatic insufﬁciency is decreased
nd the efﬁciency of complex physical therapy is improved (Fig. 3)
19].
In 2012, Huang et al. showed that for leucocytes to migrate
nto inﬂammatory tissue an efﬁcient adhesion is required [33].
herefore, monocytes and leucocytes express endothelial adhesion
olecules. Sodium selenite supplementation (2 g/ml selenium
s sodium selenite for 16 h) induced metalloproteinase-dependent
-selectin, which resulted in decreased monocyte rolling and adhe-
ion [35]. These effects were reversible using broad-range matrix
etalloproteinase inhibitor GM6001. Also, several studies showed
hat sodium selenite (100 nmol/l selenium as sodium selenite for
8 h or 0–2 M sodium selenite for 24 h) inhibited expression of
ascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion
olecule-1 (ICAM-1), E-selectin and P-selectin [36–38]. This new
ata supports the hypothesis of Kasseroller et al. [19].
Sodium selenite also inhibited nuclear factor-B (NFB) directly
hrough adduct formation with the essential thiols of this transcrip-
ion factor in human T cells and lung adenocarcinoma cells [39].
he inhibition was dose-dependent. Complete NFB inhibition was
eached at 7 M sodium selenite. NFB is required for transcription
f above mentioned adhesion proteins. Also, glutathione peroxi-
ase 1 and 4 inhibited NFB activation [40,41]. The inhibitory effect
f sodium selenite on NFB depends on both, biological and phar-
acological, effects. NFB also plays a major role in inﬂammation.
ro-inﬂammatory cytokines activate NFB and NFB induces the
xpression of cytokines, chemokines, and adhesion molecules [42].
he inhibition of NFB by sodium selenite is probably one reason
or the anti-inﬂammatory effect of sodium selenite in lymphedema.
.6. Prospective trials
There are several questions the previous trials did not answer.
irst of all, the patients were treated with sodium selenite only for
 few weeks. But both, primary and secondary lymphedema, are
ifelong conditions. Therefore, future trials should be designed to
nswer the question: How long should treatment last? The dura-
ion of trials in other indications such as during radiotherapy or
n sepsis patients, which also used high dose sodium selenite, was
lso only weeks [27,43]. In these trials high dose sodium selen-
te displayed no relevant side effects. A recent trial determined the
aximum tolerable dose of sodium selenite in cancer patients [44].
he results showed that the patients displayed hardly any symp-
oms at dose levels below 3,000 g/m2. At dose level 3,000 g/m2
nd above 15% of the patients had garlic smell of breath. At dose
evel 4,500 g/m2 the most common side effects were nausea, vom-
ting, and fatigue. Those were reversible within one or two days.
hinese studies showed that only long term intake at or above
10 g per day resulted in selenosis symptoms [45].edicine and Biology 37 (2016) 111–116 115
Another question concerns the measurement of selenium level.
In lymphedema trials patients displayed low blood selenium level
[7,8]. Those patients beneﬁted from sodium selenite treatment.
Selenium measurement before therapy start and during therapy
should be useful to determine the adequate selenium dose. Future
trials should establish parameters, which selenium dose would
be sufﬁcient to increase selenium status to an adequate level. So
far there is no uniform deﬁnition of selenium deﬁciency. There
are diseases associated with selenium deﬁciency: Kashin-Beck
and Keshan disease. These selenium deﬁciency diseases mostly
occurred at a mean value of 21 g/l selenium in serum [46]. But all-
cause mortality was  increased for serum selenium concentrations
below 106 g/l [47].
Also the parameter for measurement is important: whole blood
or plasma/serum concentrations. Selenium serum concentration
reﬂects short term status. Whole blood selenium also takes into
account erythrocyte selenium and reﬂects long-term status due
to the incorporation of selenium during protein synthesis in cells
[48,49]. Hence, whole blood selenium allows a better assessment
of selenium status.
2. Conclusions
The preferred treatment of secondary lymphedema is complex
physical therapy. Pharmacotherapy has received little atten-
tion, but sodium selenite showed good results in reduction of
lymphedema volume, increasing the efﬁcacy of complex physi-
cal therapy, and in incidence reduction of erysipelas infections
in patients with cancer-related lymphedema. Besides biological
effects in reducing excessive production of ROS, sodium selenite
also displayed various pharmacological effects. Sodium selenite
can directly inhibit the expression of adhesion proteins and NFB.
The positive effect of sodium selenite on infection risk probably
depends on both, biological and pharmacological, effects. Further
trials are needed to conﬁrm these results and to specify selenium
dosage and therapy duration.
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